Research Article

Crystal Journal of Medical Research

Carbetocin Versus Oxytocin in the Prevention of Postpartum Haemorrhage in Caesarean Section: A Prospective Randomised Comparative Study

Dr. Farah Munazira[1]*, Dr. Zarin Rahman[2], Dr Poonam Lal[3], & Dr. Naaz Ahmed[4]

[1]MBBS, DGO, DNB, Kurji holy family hospital, Patna, Bihar-800010, India
[2]MBBS, MD, FRCOG, Senior Consultant, Kurji Holy Family Hospital, Patna, Bihar-800010, India
[3]MBBS, MS, Consultant, Kurji Hoy Family Hospital, Patna, Bihar-800010, India
[4]MBBS, MS, Assistant professor, Netaji Subhash Medical College, Bihta, Patna, India

Corresponding Author: Dr. Farah Munazira, MBBS, DGO, DNB, Kurji holy family hospital, Patna, Bihar-800010, India.

Cite: Munazira F, Rahman Z, Lal P, Ahmed N. Carbetocin versus oxytocin in the prevention of postpartum haemorrhage in caesarean section: a prospective randomised comparative study. Cryst J Med Res. 2025;1(1):01-08.

Received: September 17, 2025; **Accepted:** October 08, 2025; **Published:** October 16, 2025

Abstract

What does this Study Add to Clinical Work?

Considering that Oxytocin has been vital in reducing Postpartum haemorrhage (PPH) worldwide, our study was done to determine the real-world efficacy of Carbetocin. This study was conducted in one of the low-resource states in India to explore the effectiveness of Carbetocin in reducing the PPH in elective caesarean section. The use of Carbetocin has not been popular in our state. Understanding its effectiveness can improve maternal care in a region where healthcare resources may be limited and can potentially lead to changes that can benefit women across the state to combat the mortality and morbidity due to PPH.

Background: *Postpartum haemorrhage is the leading cause of maternal mortality. The prevention of PPH can be best done by active management of the third stage of labour. Oxytocin is currently the uterotonic of choice.*

Purpose: *The study compared the efficacy of Carbetocin 100 mcg intravenous bolus and Oxytocin 10 IU intravenous infusion over 2 hours by measuring total blood loss, the need for additional uterotonic agents, and the need for blood transfusion. It is important to evaluate the efficacy of Carbetocin compared to Oxytocin in low-income countries, especially where patient affordability is a major concern.*

Method: *A prospective randomised comparative single-blinded study was conducted in the Department of Obstetrics and Gynaecology, Kurji Holy Family Hospital, Patna, Bihar. 100 patients undergoing elective caesarean section fitting in the inclusion criteria were randomly allocated by a sealed envelope system to either case study group A receiving Carbetocin 100 mcg intravenous and control study group B receiving Oxytocin 10 IU intravenous infusion. Three specific outcomes were measured: total blood loss, additional uterotonic use and the need for blood transfusion.*

Results: *In this study, Carbetocin was found to significantly reduce total blood loss in comparison to oxytocin($p<0.0001$), the use of additional uterotonics was significantly less in the Carbetocin group ($p=0.023$), the need for blood transfusion was less in Carbetocin group but not significantly ($p=0.538$).*

Conclusion: *Carbetocin has better efficacy in comparison to oxytocin in reducing total blood loss, hence preventing PPH. The need for additional uterotonic agents is less with Carbetocin use. The need for blood transfusion was also less with Carbetocin use but needs larger studies to be proved. Carbetocin may be cost-effective.*

Keywords

Carbetocin, Oxytocin, Postpartum Haemorrhage, Caesarean Section, Uterotonics

Introduction

Postpartum haemorrhage (PPH) is the leading cause of maternal deaths worldwide [1]. It continues to receive the attention of researchers in the medical community.

World Health Organization (WHO) defines PPH as blood loss of 500 mL or more following a vaginal delivery or 1000 mL or more following a caesarean section within 24 hours after birth[1]. PPH is the consequence of several different factors, such as uterine atony, retained placental tissue, genital tract trauma and coagulation dysfunction (the 4 T's mnemonic Tone, Tissue, Trauma and Thrombin). Most cases of PPH are caused by uterine atony [1]. Globally, PPH affects around 6-10% of all deliveries, contributing to 70,000 maternal deaths annually, which accounts for 20% of all maternal deaths worldwide [2]. In India, the incidence of PPH is notably higher compared to the global average. In 2016, Ramdurga U et al. reported in their study that in India, PPH is responsible for nearly 40% of all maternal deaths [3]. The incidence of PPH is reported as 2 to 4% after vaginal delivery and 6% after caesarean section [4].

PPH is life-threatening but preventable. It mostly occurs during the third stage of labour and active management of the third stage of labour (AMTSL) helps prevent PPH. AMTSL, as recommended by WHO, is oxytocin 10 I.U. intramuscular (IM) after the delivery of the baby, controlled cord traction by trained birth attendants [5]. AMTSL has proven to reduce the rate of severe PPH by 60% - 70% [6]. Oxytocin is currently the uterotonics of choice [5]. Oxytocin has a rapid onset of action and a good safety profile. However, oxytocin must be stored and transported at 2-8°C to maintain its effectiveness. In many countries, especially with limited resource settings and unreliable electricity, lack of temperature-controlled storage capacity, and a lack of cold chain facilities, oxytocin effectiveness is often compromised at the point of care. Another disadvantage of oxytocin is its short half-life of 4 to 10 minutes, regularly requiring a continuous intravenous infusion [7]. Carbetocin is a long-acting Oxytocin analogue indicated for the prevention of uterine atony after childbirth. There are two forms of Carbetocin: heat-stable Carbetocin and non-heat-stable Carbetocin [8]. Both forms are equally effective in preventing PPH. However, the newer heat-stable version offers a logistical advantage without compromising on efficacy but may be more expensive. It is heat-stable and does not require cold-chain transport and storage. It maintains its stability over 36 months at 30°C and 75% relative humidity. Carbetocin has a rapid onset of action (within 1 to 2 minutes) and a prolonged duration of action (approximately one hour). Its safety profile is comparable with that of oxytocin. Carbetocin has a much longer half-life of 85-100 minutes [9]. The WHO conducted a large Carbetocin haemorrhage prevention (CHAMPION) Trial, which concluded that Carbetocin is non-inferior to oxytocin in the prevention of PPH [10].

WHO's recommendations on uterotonics, 2018 recommend heat-stable Carbetocin for the prevention of PPH after all births in settings where oxytocin is unavailable, or its quality cannot be guaranteed and where its cost is comparable to other effective uterotonics [11].

Reduction in re-treatment, staffing requirements, transfusion and potential medication errors from faulty cold-chain maintenance mitigate the higher index cost of Carbetocin. Studying the efficacy of this drug in the prevention of PPH is important in India, a developing nation where the affordability of patients is a major concern.

In this backdrop, the study was conducted to compare Carbetocin versus Oxytocin for the prevention of postpartum haemorrhage during elective caesarean among Indian pregnant women. Considering that Oxytocin has been vital in reducing PPH worldwide, our study was done to determine the real-world efficacy of Carbetocin. This study was conducted in one of the low-resource states in India to explore the effectiveness of Carbetocin in reducing the PPH in elective caesarean section. The use of Carbetocin has not been popular in our state. Understanding its effectiveness can improve maternal care in a region where healthcare resources may be limited and can potentially lead to changes that can benefit women across the state to combat the mortality and morbidity due to PPH. To our knowledge, there are no studies on Carbetocin in our State to date. This study may serve as a foundation for further regional studies where maternal health is a key concern.

Aims and Objectives

To compare the efficacy of Carbetocin 100 mcg intravenous (IV) with that of oxytocin 10 IU infusion in elective caesarean section in the prevention of PPH. Three specific outcomes: total blood loss, use of additional uterotonics, and need for blood transfusion were recorded.

Materials and Method

Study Design and Participants

A prospective randomised controlled trial was conducted in the Department of Obstetrics and Gynecology, Kurji Holy Family Hospital, Patna, Bihar, over 11 months. All primigravida and multigravida with singleton pregnancy more than 37 weeks gestational age admitted for elective caesarean section were included in the study. Patients with a history of PPH were not excluded from the study. Patients with multiple pregnancy, polyhydramnios, pregnancy-induced hypertension, macrosomia, pregnancy with maternal medical diseases including liver, brain, heart, kidney and coagulation disorders, placenta previa, placenta accreta, pregnancy with myoma and patients not willing to participate were excluded from the study.

Sample Size Calculation The study of Franco Borruto et al observed that the percentage of patients with blood loss < or=500 ml was greater with Carbetocin as compared to Oxytocin (81% vs. 55%) [12]. Taking these values as a reference, the minimum required sample size with 80% power of study and 5% level of significance is 47 patients in each study group. To reduce the margin of error, the total sample size taken is 100 (50 patients per group).

The formula used is:

$n>=((pc*(1-pc)+pe*(1-pe))*(Z\ \alpha +Z\ \beta)^2)/(pc-pe)^2$

With

- Pc=percentage of patients with blood loss < or =500 ml in Carbetocin;
- Pe=percentage of patients with blood loss &< or =500 ml in oxytocin;
- Where Z α is the value of Z at a two-sided error of 5%, and Z β is the value of Z at a power of 80%.

Calculations

- n>= {(.81 *(1-.81) +.55 *(1-.55)} *(1.96+.84) 2)/ (.81-.55) 2
- >= 46.55 ≈ 47 (approximately).
- So, the sample size in the study was taken as 50 in each group. Hence, the total sample size was 100 patients.

Data Collection and Methodology

A total of 100 women were enrolled in the study. These patients were divided into two groups: case study group A received Carbetocin 100 mcg IV bolus over 1 minute, and control group B received oxytocin 10 IU IV infusion over 2 hrs.

Each group consisted of 50 patients and was allocated by block randomisation with a sealed envelope system. In this technique, patients were randomised in a series of blocks of ten.

- In this, we prepared 10 randomly generated treatment allocations within sealed opaque envelopes, assigning A and B in 5 envelopes each, where A represents the Carbetocin group and B represents the Oxytocin group.
- Once a patient gave consent to enter the trial, an envelope was picked up by the patient.
- The patient was not aware which group had been allocated to her as the envelopes were sealed and opaque, making the study single-blinded.

The patients underwent a caesarean section under spinal anaesthesia as per the standard protocols of our department. The patient was given the uterotonic based on the group to which it belonged after the delivery of the baby once the umbilical cord was clamped. Delayed cord clamping [1] is the standard protocol of our institution. All the sponges used during surgery were weighed before and after the surgery. Using the gravimetric method, blood loss was calculated. We used the WHO definition for PPH, which is blood loss exceeding 500 mL following vaginal delivery and 1,000 mL following caesarean delivery [1]. Two suction bottles were used, one for amniotic fluid and the other for blood. Weight of the pads used 2 hours postoperatively were weighed.

- Intra-operative (in mL) = (weight of used sponges during – the weight of dry sponges before the surgery) + volume of blood sucked in the suction bottle.
- 2 hours postpartum blood loss (mL) = weight of pad used after completion of caesarean section up to 2 hours postpartum was separately weighed.
- Total blood loss (ml) = intraoperative blood loss (ml) + 2 hours postpartum blood loss.
- Gravimetric method: every gram of weight equivocal to 1 mL of blood loss.

It was assumed that weight is only due to the blood and not environmental water or debris.

Total blood loss was calculated as intraoperative and 2 hours postoperative. The use of additional uterotonics intraoperative was noted. The need for blood transfusion 48 hours postoperative was noted.

Statistical Analysis

Categorical variables were presented in number and %, and continuous variables were presented as mean +/- SD and median. Normality of data tested by Kolmogorov-Smirnov test. If the normality was rejected, then a non-parametric test was used.
Statistical test was applied as follows-

1. Quantitative variables were compared using an unpaired t-test/Mann-Whitney test (when the data sets were not normally distributed) between the two groups.
2. Qualitative variables were compared using the chi-square test/Fisher exact test.

A p-value of <0.05 is considered statistically significant. The data was entered in an MS EXCEL spreadsheet, and analysis was done using the Statistical Package for Social Sciences (SPSS) version 21.0.



Figure 1: Chart

Results

The baseline characteristics like age, parity, body mass index (BMI) and indication for elective caesarean section are summarised in (Tables 1, 2, 3, 4). Distribution of age (years) was comparable between groups A and B (20-30 years: - 66% vs 70% respectively, 31-40 years: - 34% vs 30% respectively) (p value=0.668). The mean ± SD of age(years) in group A was 28.28 ± 4.47, and in group B was 27.6 ± 4.58 with no significant difference between them (p value=0.455) (Table 1).

Table 1: Comparison of age (years) between groups A and B.

Age(years)	A(n=50)	B(n=50)	Total	P value
20-30	33 (66%)	35 (70%)	68 (68%)	0.668†
31-40	17 (34%)	15 (30%)	32 (32%)	
Mean ± SD	28.28 ± 4.47	27.6 ± 4.58	27.94 ± 4.52	0.455‡
Median (25th- 75th percentile)	27(25.25-31.75)	28(23.25-31)	27(24.75-31)	
Range	20-38	21-40	20-40	

‡ Independent t-test, † Chi-square test

Distribution of body mass index (BMI)(kg/m²) was comparable between groups A and B. (18.5 to 24.99 kg/m² {Normal BMI}: - 0% vs 2% respectively, 25 to 29.99 kg/m² {Overweight}:- 76% vs 62% respectively, >=30 kg/m² {Obese}: - 24% vs 36% respectively) (p value=0.194) (Table 2). The mean ± SD of body mass index(kg/m²) in group A was 29.23 ± 1.45, and in group B was 29.36 ± 2.34(p=0.753) (Table 2).

Table 2: Comparison of body mass index (BMI) between groups A and B.

BMI (kg/m2)	A(n=50)	B(n=50)	Total	P value
18.5 to 24.99	33 (66%)	35 (70%)	68 (68%)	0.194*
{Normal BMI}	0 (0%)	1 (2%)	1 (1%)	
25 to 29.9	28.28 ± 4.47	27.6 ± 4.58	27.94 ± 4.52	
{Overweight}	38 (76%)	31 (62%)	69 (69%)	
>=30 {Obese}	12 (24%)	18 (36%)	30 (30%)	
Mean ± SD	29.23 ± 1.45	29.36 ± 2.34	29.29 ± 1.94	0.753‡
Median (25th-75th percentile)	29.14(28.298-29.952)	29.01(27.445-30.731)	29.14(28.03-30.366)	
Range	26.67-32.89	24.6-36.16	24.6-36.16	

‡ Independent t-test, * Fisher's exact test

Distribution of parity(P) was comparable between groups A and B. (P0: - 38% vs 36% respectively, P1: - 46% vs 44% respectively, >=P2: - 16% vs 20% respectively) (p value=0.873). (Table 3).

Table 3: Comparison of obstetric history between groups A and B.

Obstetric history	A(n=50)	B(n=50)	Total	P value
Parity(P)				
P0	19 (38%)	18 (36%)	37 (37%)	0.873†
P1	23 (46%)	22 (44%)	45 (45%)	
>=P2	8 (16%)	10 (20%)	18 (18%)	

† Chi-square test

Distribution of indication of caesarean was comparable between groups A and B. (Breech: - 12% vs 10% respectively, CPD:- 6% vs 2% respectively, Failed IOL:- 14% vs 16% respectively, IUGR:- 6% vs 2% respectively, Maternal wish:- 8% vs 6% respectively, Previous 1 CS:- 38% vs 40% respectively, Previous 2 CS:- 14% vs 20% respectively, Previous myomectomy:- 2% vs 2% respectively, Transverse lie:- 0% vs 2% respectively) (p value=0.924). (Table 4).

Table 4: Comparison of indication of caesarean section (CS) between groups A and B.

Indication of CS	A(n=50)	B(n=50)	Total	P value
Breech	6 (12%)	5 (10%)	11 (11%)	0.924*
Cephalopelvic disproportion	3 (6%)	1 (2%)	4 (4%)	
Failed IOL*	7 (14%)	8 (16%)	15 (15%)	

IUGR	3 (6%)	1 (2%)	4 (4%)	
Maternal wish	4 (8%)	3 (6%)	7 (7%)	
Previous 1 CS	19 (38%)	20 (40%)	39 (39%)	
Previous 2 CS	7 (14%)	10 (20%)	17 (17%)	
Previous myomectomy	1 (2%)	1 (2%)	2 (2%)	
Transverse lie	0 (0%)	1 (2%)	1 (1%)	
Total	50 (100%)	50 (100%)	100 (100%)	

* Fisher's exact test

Carbetocin use reduced blood loss from placental delivery to end of caesarean section compared to oxytocin group (339.8 +_130.24 mL vs 470.4 +_156.84 mL respectively) (p< 0.0001) as well as 2 hours postpartum (in case group 55. 88+_22.13 mL compared to control group 72.2+_26.9 mL) (p<0.0001) (Table 5). Total blood loss was also significantly lower in the Carbetocin group compared to oxytocin (p<0.0001) (Table 5). The Carbetocin group had a lower number of PPH cases, 4%, as compared to the oxytocin group, 6% (Table 5). Additional uterotonics were statistically less in the Carbetocin group (16%) compared to the oxytocin group (36%) (p=0.023) (Table 6). No surgical methods or tamponades were used to control the PPH. 5 patients in the Carbetocin group and 7 in the oxytocin group required blood transfusion(p=0.538) (Table 7). No massive transfusion was required in either group.

Table 5: Comparison of blood loss(mL) between groups A and B.

Blood loss(mL)	A(n=50)	B(n=50)	Total	P value
Total blood loss(mL)				
Mean ± SD	395.68 ± 147.93	470.4 ± 156.84	433.04 ± 156.26	<.0001§
Median (25th-75th percentile)	360(340-390)	440(410-470)	400(360-460)	
Range	310-1140	360-1150	310-1150	
Blood loss from placental delivery till uterus closure(mL)				
Mean ± SD	339.8 ± 130.24	398.2 ± 135.37	369 ± 135.37	<.0001§
Median (25th-75th percentile)	310(292.5-340)	380(342.5-387.5)	340(300-380)	
Range	250-1000	300-950	250-1000	
Blood loss 2 hours post caesarean section (mL)				
Mean ± SD	55.88 ± 22.13	72.2 ± 26.9	64.04 ± 25.84	0.0002§
Median (25th-75th percentile)	50(40-60)	80(60-80)	60(40-80)	
Range	40-140	40-200	40-200	
PPH cases Reported in the samples (>=1000 mL)	2 (4%)	3 (6%)	5 (5%)	-

§ Mann Whitney test, * Fisher's exact test

PPH Postpartum haemorrhage

Table 6: Comparison of use of additional uterotonics between groups A and B.

Use of additional uterotonics	A(n=50)	B(n=50)	Total	P value
No	42 (84%)	32 (64%)	74 (74%)	0.023†
Yes	8 (16%)	18 (36%)	26 (26%)	
Total	50 (100%)	50 (100%)	100 (100%)	

† Chi-square test

Table 7: Comparison of need for blood transfusion between groups A and B.

Need for blood transfusion	A(n=50)	B(n=50)	Total	P value
No	45 (90%)	43 (86%)	88 (88%)	0.538†
Yes	5 (10%)	7 (14%)	12 (12%)	
Total	50 (100%)	50 (100%)	100 (100%)	

† Chi-square test

* IOL induction of labour IUGR intrauterine growth retardation CS: caesarean section. Failed IOL: This study includes cases where induction was attempted for post-term pregnancy without maternal or foetal compromise, thereby, caesarean section was

done as elective in category 4 as per the National Institute of Care Excellence (NICE) guideline[13].

Discussion

Carbetocin is a long-acting, synthetic analogue of oxytocin that does not require cold-chain transport and storage. The half-life of Carbetocin is 4-10 fold longer than oxytocin and can be administered as a single dose injection either intravenously or intramuscularly rather than as an infusion over several hours, as is the case with oxytocin [7]. Carbetocin is being investigated by several trials for its effectiveness in preventing PPH in caesarean section and vaginal delivery. This study aims to evaluate the efficacy of Carbetocin in comparison to oxytocin for the prevention of PPH in elective caesarean section. Our findings demonstrate that Carbetocin is more effective in reducing total blood loss and the need for additional uterotonics, with fewer cases of PPH observed in the Carbetocin group. The need for blood transfusion was less in the Carbetocin group.

Baseline Characteristics

The possible confounding factors like age, BMI, parity, and indication of caesarean section were comparable in both groups. Stratifying participants by key demographic and clinical factors like age, BMI, and parity ensures that different subgroups are equally represented in both treatment and control groups. This helps in enhancing the external validity of findings. Diverse representation improves generalizability. To minimise the variation due to other factors, we included only cases of elective caesarean section with no significant difference in the indications of caesarean section in both groups.

Reduction in Blood Loss

Carbetocin significantly reduced the total blood loss during elective caesarean section in patients at low risk for PPH as compared to oxytocin. The finding is similar to other studies. Ibrahim et al.,2020, showed that blood loss was significantly more in oxytocin than in Carbetocin group 679.5+-200.25 vs 424.75 +-182.59 respectively ($p<0.001$) [14]. Meta-analysis of RCT in the caesarean section comparing oxytocin and Carbetocin for the prevention of PPH by Hian Yan Voon et al.,2017 showed a significant reduction in the rates of PPH($p=0.009$) when Carbetocin was used rather than oxytocin [15]. Carbetocin's prolonged duration of action likely contributes to its superior ability to control blood loss compared to oxytocin, which has a much shorter half-life and requires continuous infusion. Although the difference in PPH cases between the two groups was small (4% in the Carbetocin group vs. 6% in the oxytocin group), it reinforces the overall trend of reduced blood loss with Carbetocin.
Need for additional uterotonics.

One of the most notable findings of our study was the reduced need for additional uterotonics in the Carbetocin group. Only 16% of patients in this group required additional uterotonics, compared to 36% in the oxytocin group. Similar results are shown in several studies. Shayma Al Zubaidi et al. 2021 study showed that Carbetocin was superior to oxytocin by 12% in reducing the need for additional uterotonics [16]. Attilakos G et al.,2010 study reported a higher need for additional oxytocics in the oxytocin group compared with Carbetocin group (45.5%vs33.5%respectively) (RR 0.74,95% CI0.57- 0.95) [17]. The reduction in the need for additional uterotonic suggests better uterine contraction, lowering the risk of bleeding. The use of additional uterotonic was at the discretion of the surgeon. It was most often carboprost followed by misoprostol. Methergin was used in very few cases. None of the cases required tamponades or surgical interventions related to PPH. Uterine atony may result in PPH and requires intensified monitoring and prolonged observation time in the recovery room with increased use of medical staff time. Therefore, the use of additional uterotonics is an important surrogate measure of financial savings.

Blood Transfusion

Blood transfusion requirement was less in the Carbetocin group as compared to the oxytocin group, but not statistically significant. Our results are consistent with studies of Maged et al., which showed that the Carbetocin group had less blood transfusion requirement than the oxytocin group (12% vs18%) but not statistically significant ($p=0.401$) [18]. The blood transfusion requirement intraoperatively till 48 hours was noted. A total of 12 patients required blood transfusion, of which 5 of them were in the Carbetocin group and 7 in the oxytocin group. This suggests that, while both drugs are effective in preventing severe haemorrhage, Carbetocin may offer a slight advantage in reducing the need for transfusions in some cases.

The main limitations of this study were a small cohort including only elective caesarean section, blood loss was measured only after placental delivery and skin, muscle and uterine incision blood loss was not considered. Blood absorbed over the drape sheet was not considered. The use of additional uterotonic agents per-operatively was subjective to the surgeon.

Given Carbetocin's longer duration of action and its stability in higher temperatures, it presents a practical advantage in resource-limited settings. Our findings support the use of Carbetocin as a viable alternative to oxytocin. Further studies focusing on cost-effectiveness and long-term outcomes are needed.

Conclusion

The findings of this Prospective Randomised Comparative Study confirm that both Carbetocin and Oxytocin are effective uterotonic agents for the prophylaxis of postpartum haemorrhage (PPH) following elective Caesarean section.

Our data demonstrated that Carbetocin was significantly more effective than Oxytocin in reducing the incidence of PPH (blood loss ≥500 mL) and the requirement for additional, rescue uterotonic drugs. The lower mean estimated blood loss observed in the Carbetocin group suggests a more consistent and sustained uterotonic effect, which is particularly valuable in high-risk settings or resource-constrained environments where rapid access to advanced care for PPH may be limited. Given Carbetocin's single-dose administration and superior efficacy profile, it presents a compelling, ready-to-use alternative to the standard regimen of Oxytocin infusion for PPH prevention in Caesarean sections.

A key limitation of this study is its single-centre design and the potential for a small volume of subjective blood loss estimation. Future multi-centre trials with larger sample sizes and objective blood loss measurement techniques (such as gravimetric measurement) are warranted to further generalize these findings. Re-

search should also focus on a comprehensive cost-effectiveness analysis to fully assess Carbetocin's long-term feasibility for widespread adoption in public health programs in developing nations.

In summary, Carbetocin should be considered the preferred first-line uterotonic agent for PPH prophylaxis in elective Caesarean section, offering enhanced safety and efficacy over Oxytocin.

Abbreviations

- **PPH:** postpartum haemorrhage
- **IU:** international units
- **mcg:** microgram
- **mL:** millilitres
- **AMTSL:** active management of the third stage of labour
- **BMI:** body mass index
- **CPD:** cephalopelvic disproportion
- **IOL:** induction of labour
- **IUGR:** intrauterine growth retardation
- **CS:** caesarean section

Acknowledgements

The authors would like to thank all the doctors, nurses, and staff of the Department of Obstetrics and Gynaecology for their kind support during the study and express their sincere gratitude and respect to all patients who participated in it.

Author Contributions

All authors contributed to the study's conception and design.

- **Dr. F Munazira:** Protocol development, data collection, manuscript writing
- **Dr. Z Rahman:** Protocol development, manuscript editing
- **Dr. P Lal:** Protocol development
- **Dr. N Ahmed:** Data collection

All authors contributed to the study's conception and design. Material preparation, data collection and analysis were performed by Dr Farah Munazira, Dr Zarin Rahman, Dr Poonam Lal and Dr Naaz Ahmed. The first draft of the manuscript was written by Dr.Farah Munazira, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Statements & Declarations

Funding: The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Competing Interests

The authors have no relevant financial or non-financial interests to disclose.

Ethical Approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained and granted by the Ethical Committee. ICMR-Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna (ECR/480/Inst/RR/2014/RR-20)

Study Registration Number

RMRI/EC/18/2022. Date: 04/07/2022

Consent to Participate

Informed consent was obtained from all individual participants included in the study.

Consent to Publish

Informed consent for publication of data was taken from all the participants.

References

1. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization; 2012. Accessed 2024 Nov 27. Available from: https://iris.who.int/handle/10665/75411
2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–e333.
3. Shrivastava P, Lawrence S. Causes of maternal mortality rate: postpartum haemorrhage - a major cause in Madhya Pradesh. Int J Nurs Midwifery Res. 2021 Dec;8(4):4. Accessed 2024 Dec 28. Available from: https://medical.advancedresearchpublications.com/index.php/IntlJ-Nursing-MidwiferyResearch/article/view/1061
4. Federation of Obstetric and Gynaecological Societies of India. PPH Prevention and Management: Updated PPH Guidelines September 2022. 2022 Sep. Available from: https://www.fogsi.org/wp-content/uploads/tog/pph-prevention-and-management-updated-sept-2022.pdf
5. Gülmezoglu AM, Souza JP, Widmer M, Hofmeyr GJ, Carroli G, D'Souza H, et al. Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet. 2012 May;379(9827):1721–7. doi: 10.1016/S0140-6736(12)60206-2.
6. Gülmezoglu AM, Widmer M, Souza JP, Carroli G, D'Souza H, Hany S, et al. Active management of the third stage of labour without controlled cord traction: a randomized non-inferiority controlled trial. Reprod Health. 2009 Jan;6:2. doi: 10.1186/1742-4755-6-2.
7. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):15–20. doi: 10.1016/j.ejogrb.2009.06.018.
8. Widmer M, Souvi B, Tassie JM, D'Souza H, Mignini L, Bano F, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials. 2016 Mar;17:143. doi: 10.1186/s13063-016-1271-y.
9. Engstrøm T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998 Aug;355(2):203–10. doi: 10.1016/S0014-2999(98)00513-5.
10. Widmer M, Piaggio G, Carroli G, Ritson A, Say L, Gülmezoglu AM. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018 Aug;379(8):743–52. doi: 10.1056/NEJMoa1805489.
11. Tunçalp Ö, Souza JP, Gülmezoglu M. New WHO recommendations on prevention and treatment of postpartum hemorrhage. Int J Gynaecol Obstet. 2013 Dec;123(3):254–6. doi: 10.1016/j.ijgo.2013.06.024.

12. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009 Nov;280(5):707–12. doi: 10.1007/s00404-009-0973-8.
13. National Institute for Health and Care Excellence. Recommendations | Caesarean birth | Guidance | NICE. 2024 Oct 17. Available from: https://www.nice.org.uk/guidance/ng192/chapter/recommendations
14. Ibrahim ZM, Sayed Ahmed WA, Abd El-Hamid EM, Taha OT, Elbahie AM. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in hypertensive women undergoing elective cesarean section. Hypertens Pregnancy. 2020 Jul;39(3):319–25. doi: 10.1080/10641955.2020.1768268.
15. Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: a meta-analysis of randomized controlled trials in cesarean deliveries. Taiwan J Obstet Gynecol. 2018 Jun;57(3):332–9. doi: 10.1016/j.tjog.2018.04.002.
16. Al Zubaidi S, Alhaidari T. Heat stable carbetocin vs. oxytocin for the prevention of post-partum hemorrhage in emergency caesarean delivery: a randomized controlled trial. J Perinat Med. 2022 Feb;50(2):150–6. doi: 10.1515/jpm-2021-0206.
17. Attilakos G, Psaroudakis D, Ash J, Ugwumadu A, Dhanjal M, Rodeck C, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG. 2010;117(8):929–36. doi: 10.1111/j.1471-0528.2010.02585.x.
18. Maged AM, Hassan AM, Shehata NA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J Matern Fetal Neonatal Med. 2016 Feb;29(4):532–6. doi: 10.3109/14767058.2015.1011121.